Longitudinal study of older cyclists establishes baseline of biological aging in active cohorts

A 9-year longitudinal study of older cyclists demonstrates that continuous high-level exercise maintains physiological function far superior to general reference populations but cannot fully halt age-related declines in V̇O2peak and lean muscle mass.

Researchers conducted a nine-year longitudinal study tracking 82 active older cyclists (originally 125, aged 64-86 years at follow-up) to evaluate physical decline independent of sedentary lifestyle factors.

The primary outcome, peak oxygen consumption (V̇O2peak), declined by 19.7% from 44.1 to 35.4 ml·kg⁻1·min⁻1 over the nine-year period.

Lean tissue mass decreased by 8.1%, and average body fat percentage increased from 23.8% to 29.2%, though resting blood pressure and metabolic markers remained within normal ranges.

Despite the decline, 98.7% of the participants who completed the test scored at or above the 90th percentile for V̇O2peak compared to general reference populations.

Participants with compromised health experienced a sharper V̇O2peak decline of 24.2% compared to a 17.3% decline in optimal agers who remained free of disease.

The study provides rare longitudinal data on human physiological aging by isolating intrinsic biological decay from the negative consequences of physical inactivity.

It confirms that while high-level exercise preserves a substantial physiological reserve—keeping almost all participants in the top decile of fitness—it does not halt the fundamental processes that drive sarcopenia and respiratory decline.

The accelerated decline seen in individuals with compromised health highlights how chronic age-related pathologies (primarily cardiovascular) interact with and accelerate intrinsic biological aging.

The persistent 8.1% decline in lean mass among highly active seniors highlights a market need for therapeutic interventions targeting muscle wasting and sarcopenia, where exercise alone is insufficient.

Developers of longevity therapeutics targeting metabolic and tissue aging can use these longitudinal decline rates to design clinical trials and establish efficacy relative to an active, optimal aging baseline.

Future studies exploring the underlying molecular and cellular mechanisms that drive the observed 19.7% cardiorespiratory decline, which could highlight therapeutic targets for age-related aerobic decline.